Registry Platform Urologic Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsoriOMEDICO AG
About this trial
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or urothelial cancer in Germany.
Eligibility criteria
Qualifiers
Female and male patients with aRCC or aUBC (locally advanced, inoperable or metastatic)
Patients at start of their first-line systemic treatment for aRCC or aUBC
Written informed consent
Patients participating in the PRO module: signing of in-formed consent form and completion of baseline questionnaire before start of initial systemic treatment
Disqualifiers
Patients with prior systemic therapy for aRCC or aUBC
No systemic treatment for aRCC or aUBC
Partial cystectomy or partial nephrectomy of the primary tumor as definitive therapy
Metastatic disease (M1) at the time of surgery
Trial design
Treatments tested in this trial
- Routine care as per site standard.
Treatment groups
1,930 Participants
are divided into 3 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Multiple sites, GermanyRecruiting Multiple Locations
Germany
GermanySponsors and collaborators
Source ClinicalTrials.gov